2 ASX 200 shares with multi-decade growth runways: Scott Phillips

After a devastating year for investors in 2022, perhaps it's time to buy stable, reliable ASX 200 shares to help you ride out this period of economic volatility.

| More on:
a mature but cool older woman holds a watering can and tends to a healthy green plant growing up the wall in her house.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're "over the market volatility", it may be time to buy blue-chip ASX 200 shares that won't deliver spectacular returns over the short term but will deliver reliable earnings and growth over the long term.

That's the advice of Motley Fool Australia's chief investment officer, Scott Phillips, who chatted with Gemma Dale on nabtrade's Your Wealth podcast yesterday.

Phillips nominated two ASX healthcare shares with "multi-decade runways" for growth based on long-term social trends. Both are large-cap shares in the S&P/ASX 200 Index (ASX: XJO).

The 'long-term winners' for growth this year

Phillips said the economy is in a state of flux and no one really knows what's going to happen next.

In such tumultuous times, he reckons "long-term winners are really, really, really attractive" because they offer earnings stability and good growth prospects.

Phillips said:

… if you can do moderately well for a very long period of time as an investor, you'll do very well overall.

And if you can buy businesses that are in that space that just continue to compound away, grind away and just get bigger and bigger and bigger, and more and more successful over time, I think that's an opportunity there.

Which two ASX 200 shares should you buy?

The two ASX 200 shares Phillips recommends are Cochlear Limited (ASX: COH) and Resmed CDI (ASX: RMD).

Phillips likes these ASX 200 shares because the world is getting older and fatter, and these companies are the market leaders in their respective fields of helping people hear and helping them sleep.

Why buy Cochlear shares?

Cochlear is the world's leading hearing implant device manufacturer. Its implants are the standard of care for children with severe or profound hearing loss. The company also sells products to seniors once their normal hearing aids are no longer effective.

Phillips said:

It's a medically diagnosed condition [and] Cochlear is the leader in this space. They are in a business that is going to have more and more people diagnosed over time because medical science gets better, the world is becoming more affluent so the developing worlds … will be able to afford some of this technology … and if you're a Cochlear customer, you're a Cochlear customer effectively for life — it's an implanted device.

Why buy Resmed shares?

Resmed is a global leader in sleep technology. It develops, manufactures, and distributes medical devices such as CPAP masks, and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders. These include sleep apnoea, which is common among obesity sufferers, and chronic obstructive pulmonary disease (COPD).

Phillips said:

… sleep apnoea is a continuing issue, the world is getting fatter, we're getting older, the growth in the diagnosis of sleep apnoea continues to be huge, so these are companies I think with literally multi decade runways.

They're not going to be spectacular growth, they're not going to give you Afterpay-like returns over six or 18 months but these are just great businesses that I think have a really great long term future.

Phillips said as the market leaders, the two ASX 200 companies had excellent prospects for revenue growth, which bodes well for share price appreciation.

He said: "As long as you remain the brand of choice, that's a pretty good way to keep that cash rolling."

Also during the interview, Phillips discussed what investors could do to set their portfolios up for success in today's difficult economic environment.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »